PursueCare, a company that provides personalized virtual addiction treatment, announced the re-release of FDA-cleared RESET and RESET-O, prescription digital therapeutics (PDTs) for substance use disorder and opioid use disorder, respectively.
RESET and RESET-O were initially developed and commercialized by Pear Therapeutics, which filed for Chapter 11 bankruptcy last year. PursueCare acquired...
Digital therapeutics company Big Health announced it acquired Limbix, a maker of prescription digital therapeutics aimed at treating depression in teens and young adults.
Limbix is the creator of SparkRx, a PDTx that uses the principles of cognitive behavioral therapy to address depression in teens and young adults ages 13 to 22.
The self-guided CBT-based treatment was released in October 2021...
Editor's note: This story has been updated with additional information from a filing with the Securities and Exchange Commission.
Pear Therapeutics, maker of prescription digital therapeutics, announced today that it has filed for Chapter 11 bankruptcy and is seeking a sale of its business or assets.
The company will continue its scaled-down operations during Chapter 11 as it seeks a sale, and...
Better Therapeutics, a prescription digital therapeutics company, announced a private placement of the company's common stock, which garnered gross proceeds of approximately $6.5 million.
Officers and directors of the company participated in the placement, which is expected to close on or around April 10.
Better Therapeutics was among the many digital health companies that went public by merging...
Better Therapeutics, a prescription digital therapeutics platform, has laid off approximately 35% of its workforce due to a cost reduction initiative, according to a U.S. Securities and Exchange Commission filing on Friday.
The company provides cognitive behavioral therapy to address diabetes, hypertension and other cardiometabolic diseases.
Per the SEC filing, the company expects to incur...
At the tail end of 2022, Click Therapeutics announced it was expanding its partnership with Boehringer Ingelheim focused on developing prescription digital therapeutics for patients with schizophrenia.
Pharma partnerships aren't new for digital health players, or for Click, which has several products in its development pipeline. The company's chief strategy officer, Austin Speier, said Click...
New legislation would allow for reimbursement of prescribed digital therapeutics under Medicare, which proponents argue could increase access to these emerging treatments. Still, others say it's new technology, and the wrong reimbursement model could tamper innovation and increase patient costs.
The Access to Prescription Digital Therapeutics Act of 2022, introduced in the U.S. Senate in March...
Pharma company Boehringer Ingelheim and Click Therapeutics announced an expanded partnership to develop and commercialize another prescription digital therapeutic for patients with schizophrenia.
The deal will net Click up to $460 million, plus tiered royalties. It builds on an earlier collaboration announced in 2020 that developed CT-155, an initial therapeutic for schizophrenia.
The companies...
Pediatric behavioral health company Brightline is launching a virtual coaching program aimed at parents and caregivers with children at risk for or diagnosed with autism spectrum disorder (ASD).
Getting an Early Start on Autism includes one-on-one sessions with an autism care coach as well additional educational content and exercises. The program is geared toward caregivers with children ages 18...
Happify Health announced Monday it has entered into an agreement with healthcare services and pharmaceutical company Zuellig Pharma to commercialize two of its prescription digital therapeutics in Asia.
The deal includes Ensemble, Happify's therapeutic for treating major depressive disorder and generalized anxiety disorder, and a prescription digital therapeutic for chronic insomnia. The PDTs...
